LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy.

J Exp Med · 2021 · PMC8117208 · PMID 33974041

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Skin cutaneous melanoma and bladder cancer (data not shown), although not significant, showed a trend of higher LILRB4 compared with normal tissue.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.